| |JUNE 20269JOHNSON & JOHNSON BRINGS PULSED FIELD ABLATION TECH TO INDIADELHI HIGH COURT ASKS CDSCO TO REVIEW ZYDUS SEMAGLUTIDE APPROVALINTRACIN PHARMA SECURES APVMA APPROVAL FOR AUSTRALIA EXPANSIONAKUMS RECEIVES EUROPEAN CEP APPROVAL FOR CEFPODOXIME PROXETILIntracin Pharma has secured APVMA approval for Australia expansion, marking a major milestone for the Indian veterinary pharmaceutical company as it prepares to supply veterinary medicines in one of the world's most tightly regulated animal healthcare markets. The approval is expected to strengthen the company's international presence and boost confidence in Indian veterinary medicines.The approval, granted by the Australian Pesticides and Veterinary Medicines Authority (APVMA), allows Intracin Pharma to enter Australia's veterinary healthcare market, known for its strict quality and safety standards. For the company, this is not only an opportunity to expand exports but also recognition of its manufacturing quality and regulatory compliance. POThe Delhi High Court has directed the Central Drugs Standard Control Organization (CDSCO) to review the approval granted to Zydus Lifesciences for its semaglutide injections, bringing regulatory scrutiny to one of the fastest-growing therapy segments in India--diabetes and weight management.Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil, marking a key milestone in its global regulatory expansion.The CEP certification confirms that Akums' manufacturing process complies with European Pharmacopoeia standards, enabling smoother access to regulated European markets and reinforcing its credibility as a global CDMO partner. POJohnson & Johnson India has introduced its advanced Pulsed Field Ablation technology in India, marking a significant development in the country's cardiac care landscape.The launch is expected to enhance treatment options for patients suffering from atrial fibrillation (AFib), a common heart rhythm disorder treatment area that increases the risk of stroke, heart failure, and other cardiovascular complications.The introduction of the technology positions India among key global markets adopting next-generation electrophysiology technology solutions for heart rhythm management.The newly launched platform is designed to treat AFib through a catheter-based ablation procedure that uses electrical pulses instead of extreme heat or cold to target problematic heart tissue. POThe approval allows the companies to market the generic version in the United States, providing an alternative treatment option for patients requiring advanced oncology therapies. Generic approvals continue to play an important role in improving access to medicines while supporting healthcare affordability. POZydus markets the drug under brands such as Semaglyn, Alterme, and Mashema. Semaglutide, a GLP-1 receptor agonist, has seen explosive global demand due to its dual role in controlling Type 2 Diabetes and enabling weight loss.However, the current legal challenge raises critical questions around product design, dosing safety, and regulatory evaluation standards in India. PO
< Page 8 | Page 10 >